Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth

Decreased cellular NAD(+) levels are causally linked to aging and aging-associated diseases. NAD(+) precursors in oxidized form such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) have gained much attention and been well studied for their ability to restore NAD(+) levels in model organisms. Less is known about whether NAD(+) precursors in reduced form can also efficiently increase the tissue and cellular NAD(+) levels and have different effects on cellular processes than NMN or NR. In the present study, we developed a chemical method to produce dihydronicotinamide mononucleotide (NMNH), which is the reduced form of NMN. We demonstrated that NMNH was a better NAD(+) enhancer than NMN both in vitro and in vivo, mediated by nicotinamide mononucleotide adenylyltransferase (NMNAT). Additionally, NMNH increased the reduced NAD (NADH) levels in cells and in mouse livers. Metabolomic analysis revealed that NMNH inhibited glycolysis and the TCA cycle. In vitro experiments demonstrated that NMNH induced cell cycle arrest and suppressed cell growth. Nevertheless, NMNH treatment did not cause an observable difference in mouse weight. Taken together, our work demonstrates that NMNH is a potent NAD(+) enhancer and suppresses glycolysis, the TCA cycle, and cell growth.

Automated summary

The study demonstrates that NMNH is a potent enhancer of NAD(+) and suppresses glycolysis, the TCA cycle, and cell growth. NMNH, produced through a chemical method, is more effective than NMN in increasing NAD(+) levels in vivo and in vitro, mediated by NMNAT.